There is presently far less information available about how lipid modification of GIPR agonists alters GIPR function or interactions with membrane lipids, probably as a result of the relatively recent interest in GIPR as a therapeutic target in type 2 diabetes and obesity compared to the GLP-1R. This evidence concerns the gene GLP1R and obesity disorder.